Literature DB >> 2438375

Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation.

R B Ferns, R S Tedder, R A Weiss.   

Abstract

Monoclonal antibodies were raised against the gag proteins of a British isolate of the human immunodeficiency virus (HIV), CBL-1. Seven of the monoclonal antibodies recognized HIV gag-coded proteins of 55,000 mol. wt. (p55) and 24,000 mol. wt. (p24), three recognized p55/p18 and three p18 alone. Cross-competition assays suggested that at least two independent epitopes exist on the p24 cleaved from the p55 precursor, whereas a cluster of closely related epitopes was recognized by the p55/p18 and p18 antibodies. The panel of monoclonal antibodies was then used to compare by immunofluorescence the expression of gag-encoded antigenic determinants on HIV isolates from different geographical locations. Minor changes in epitope expression were observed in isolates from the U.S.A. and Haiti with the most notable changes being detected in isolates from Zaire, Tanzania and Uganda.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438375     DOI: 10.1099/0022-1317-68-6-1543

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses.

Authors:  Frederick Arnaud; Sarah G Black; Lita Murphy; David J Griffiths; Stuart J Neil; Thomas E Spencer; Massimo Palmarini
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

4.  Cell surface expression of several species of human immunodeficiency virus type 1 major core protein.

Authors:  A G Laurent; B Krust; M A Rey; L Montagnier; A G Hovanessian
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.

Authors:  V Robert; M Resnicoff; J C Chermann; C Devaux
Journal:  Mol Cell Biochem       Date:  1991-04-10       Impact factor: 3.396

6.  Characterization of murine monoclonal antibodies directed against the core proteins of human immunodeficiency virus types 1 and 2.

Authors:  M Niedrig; J Hinkula; H P Harthus; M Bröker; L Hopp; G Pauli; B Wahren
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

7.  Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.

Authors:  M I Bukrinsky; N Sharova; T L McDonald; T Pushkarskaya; W G Tarpley; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Circulation of HIV antigen in blood according to stage of infection, risk group, age and geographic origin.

Authors:  J Goudsmit; D A Paul
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

10.  Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method.

Authors:  Eun-Young Kim; Jennifer Stanton; Bette T M Korber; Kendall Krebs; Derek Bogdan; Kevin Kunstman; Samuel Wu; John P Phair; Chad A Mirkin; Steven M Wolinsky
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.